Shopping Cart
Remove All
Your shopping cart is currently empty
Lapaquistat is a cholesterol biosynthesis inhibitor and is the active metabolite of TAK-475. Lapaquistat can reduce statin-induced myotoxicity in lipid-lowering therapy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $6,000 | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 100 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Lapaquistat is a cholesterol biosynthesis inhibitor and is the active metabolite of TAK-475. Lapaquistat can reduce statin-induced myotoxicity in lipid-lowering therapy. |
| Synonyms | T-91485 |
| Molecular Weight | 603.1 |
| Formula | C31H39ClN2O8 |
| Cas No. | 189059-71-0 |
| Relative Density. | 1.261g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (41.45 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (0.83 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.